Équipes de recherche
INSTITUT DE BIOLOGIE DU DEVELOPPEMENT DE MARSEILLE

Actualités

L’équipe Maina publie dans le Journal of Hepatology

L'équipe a découvert que ADAMTSL5 est un oncogène épigénétiquement activé et surexprimé chez une grande partie des patients humains atteints de HCC et dans des modèles murins de HCC.
Picture of Delphine Dauga
Delphine Dauga
Biocurator at Bioself
Date de publication

Le microenvironnement de la tumeur a des effets profonds sur l’initiation, la progression et la résistance aux médicaments du cancer. ADAMTSL5 est une protéine sécrétée par les cellules HCC, qui n’était pas auparavant liée au cancer. Nous avons découvert que ADAMTSL5 est un oncogène épigénétiquement activé surexprimé chez une grande partie des patients humains atteints de HCC et dans des modèles murins de HCC. Nous avons démontré qu’ADAMTSL5 est impliqué non seulement dans la tumorigenèse, mais aussi dans la résistance aux médicaments, car le ciblage d’ADAMTSL5 confère une sensibilité aux médicaments utilisés en clinique.

Article en anglais 

The scheme illustrates how in healthy liver (both mouse and human), ADAMTSL5 is expressed at very low levels due to the absence of methylation in the gene body CpG island. Instead, in HCC, ADAMTSL5 is overexpressed due to gene body CpG island hypermethylation. Top: ADAMTSL5 confers tumorigenicity and drug-resistance to HCC cells while its targeting resulted in sensitization to clinically relevant drugs. Additionally, demethylating agents (Decitabine) reduces ADAMTSL5 expression in HCC cells. Bottom: In HCC patients, ADAMTSL5 overexpression correlates with worse prognosis, reduced genetic alterations, and with alcohol consumption as a main risk factor in HCC patients.
The scheme illustrates how in healthy liver (both mouse and human), ADAMTSL5 is expressed at very low levels due to the absence of methylation in the gene body CpG island. Instead, in HCC, ADAMTSL5 is overexpressed due to gene body CpG island hypermethylation. Top: ADAMTSL5 confers tumorigenicity and drug-resistance to HCC cells while its targeting resulted in sensitization to clinically relevant drugs. Additionally, demethylating agents (Decitabine) reduces ADAMTSL5 expression in HCC cells. Bottom: In HCC patients, ADAMTSL5 overexpression correlates with worse prognosis, reduced genetic alterations, and with alcohol consumption as a main risk factor in HCC patients.

ADAMTSL5 is an epigenetically activated gene underlying tumorigenesis and drug resistance in hepatocellular carcinoma

Summary. The tumour microenvironment shapes tumour growth through cellular communications that include both direct interactions and secreted factors. The aim of this study was to characterize the impact of the secreted glycoprotein ADAMTSL5, whose role in cancer has not been previously investigated, on hepatocellular carcinoma (HCC).

Methylome analysis revealed hypermethylated gene body CpG islands at the ADAMTSL5 locus in both mouse and human HCC, correlating with higher ADAMTSL5 expression. ADAMTSL5 targeting interfered with tumorigenic properties of HCC cells in vitro and in vivo, whereas ADAMTSL5 overexpression conferred tumorigenicity to pre-tumoral hepatocytes sensitized to transformation by a modest level of MET receptor expression. Mechanistically, ADAMTSL5 abrogation led to reduction of several oncogenic inputs relevant to HCC, including reduced expression and/or phosphorylation levels of receptor tyrosine kinases MET, EGFR, PDGFRβ, IGF1Rβ, or FGFR4. This phenotype was associated with significantly increased sensitivity of HCC cells to clinically relevant drugs, namely Sorafenib, Lenvatinib, Regorafenib. Moreover, ADAMTSL5 depletion drastically increased expression of AXL, accompanied by a sensitization to Bemcentinib. Our results point to a role for ADAMTSL5 in maintaining the function of key oncogenic signalling pathways, suggesting that it may act as a master regulator of tumorigenicity and drug resistance in HCC.

To know more :

Journal of Hepatology 2020 Nov 13;S0168-8278(20)33758-2. doi: 10.1016/j.jhep.2020.11.008.

Maria Arechederra1, Sehrish K Bazai1, Ahmed Abdouni1, Celia Sequera1, Timothy J Mead2, Sylvie Richelme1, Fabrice Daian1, Stéphane Audebert3, Rosanna Dono1, Anthony Lozano4, Damien Gregoire4, Urszula Hibner4, Daniela S Allende5, Suneel S Apte2, Flavio Maina6
1 Aix Marseille Univ, CNRS, Developmental Biology Institute of Marseille (IBDM), UMR7288, Parc Scientifique de Luminy, Marseille (France).
2 Department of Biomedical Engineering, Cleveland Clinic Lerner Research Institute, Cleveland, OH 44195 (USA).
3 Aix-Marseille Univ, CRCM, Marseille Proteomics, INSERM, CNRS, Institut Paoli-Calmettes, Marseille, France.
4 Institut de Génétique Moléculaire de Montpellier, Univ Montpellier, CNRS, Montpellier, France.
5 Pathology Department, Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, 44195 (USA).
6 Aix Marseille Univ, CNRS, Developmental Biology Institute of Marseille (IBDM), UMR7288, Parc Scientifique de Luminy, Marseille (France).

Contact

Flavio Maina – flavio.maina@univ-amu.fr

 

Catégories

Dernières publications

AGENDA

Katia Barrett

While morphogenesis involves the coordinated movements and interactions of neighbouring

OFFRES D'EMPLOI

TWITTER